Skip to main content
. 2020 Sep 25;11(22):6748–6759. doi: 10.7150/jca.48535

Figure 3.

Figure 3

Trastuzumab (Traz) treatment affected AKT and p-AKT expression levels in BT474-TS and BT474-TR cells. Combination treatment of AKT inhibitor (GSK) and Traz in BT474-TR cells. (A) Trastuzumab treatment significantly affected AKT and p-AKT levels in BT474-TS and BT474-TR cells. (B) Trastuzumab plus GSK strongly affected the viability of BT474-TR cells. (C) Trastuzumab plus GSK increased apoptosis ratio of BT474-TR cells; (D) Expression of apoptotic proteins were examined by western blotting; (E) YAP, N-YAP, and p73 expression in BT474-TR cells after combination treatment. Data represent the mean ± standard (SD) of three independent experiments. *p < 0.05 and **p < 0.01.